Bio-Differentiating and Antiangiogenic Therapy with Gastroenteropancreatic Patients with Neuroendocrine Tumors (GEP-NETs) Abstract #744

Introduction: The outcome of patients with metastatic, progressive or recurrent neuroendocrine tumors remains poor despite the several novel therapeutic approaches.
Aim(s): To assess contribution of experimental bio-differentiating and antiangiogenic therapy with GEP-NET patients, along with metronomic application of chemotherapy, after failure of any form of oncological therapy available.
Materials and methods: Therapy according to the COMBAT schema was started with 12 patients (eight men and four women), median age 62 years. Such a therapeutic schema is based on combination of peroral antiangiogenic doses of celecoxib and fenofibrate, along with metronomic doses of chemotherapeutics (cyclophosphamide and temozolomide), together with pro-differentiating character of vitamin D /25 OH D(3), 1-25 OH D(3). Further, tumor markers of chromogranin A, NSE, TPS, and TK were assessed.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: MD Lubos Holubec

To read results and conclusion, please login ...

Further abstracts you may be interested in

#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#309 The Utility of Alpha Internexin as a Predictive Tissue Biomarker for Proliferation in Gastrointestinal and Pancreatic Neuroendocrine Tumors
Introduction: GEP-NETs are increasing but Ki-67 and CgA provide limited information regarding malignancy. A key unmet need is alternative biomarkers to assess the likelihood of local invasion or metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#641 Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Management in a Spanish University Hospital
Introduction: GEP-NETs are malignant entities poorly understood still, deserving important attention for a better management of the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Msc MD María Del Pilar Solis-Hernandez
#804 The Plasma Chromogranin A Level Predicts Survival and Tumor Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Introduction: The plasma chromogranin A (CgA) level is a reliable biomarker for identifying patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: M.D. Tsann-Long Hwang
Authors: Chou W C, Chen J S, Hsu J T, Chen T C, ...
#994 Predictive Biomarkers of Response in Patients with Extrapulmonary Neuroendocrine Tumors (EPNET) Treated with Platin-based Chemotherapy
Introduction: EPNET, particularly advanced and Grade 3 (G3) tumors are often treated with chemotherapy. While many patients experience tumor response, those rarely live for more than two years. Predictive markers could potentially help us to tailor the best treatment for these patients (pts).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: MD Juliana F Rego